Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Tumor Boards
Video Expert Opinion
Colleague Insights
Living Resources
Conferences
Sign in
Join now

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Advanced Melanoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

featured
Published in Advanced Melanoma

Expert Opinion / Cases · February 15, 2021

Disease Progression of Metastatic Melanoma on Nivolumab Monotherapy

Written by
Viola Franke MD

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Viola Franke MD

Discuss This item Follow

No comments yet, be the first to start the discussion!

  • Peter Kamen

    Feb 19, 2021

    ipi and nivo  or try a nivo and lag3 phase 3 trial

  • Galina Kharkevich

    Feb 19, 2021

    No information on BRAF status. Ipi+Nivo. If BRAFpositive BRAF/MEKi is also possible

  • Mikhail Abramov

    Feb 19, 2021

    use of combination BRAFi + MEKi possible

  • Rosane JohnsaoJohnsson n

    Feb 19, 2021

    ipi and nivo
clinical trial
if possible inhibitor BRAF and MEK

  • Alexander van Akkooi

    Mar 10, 2021

    I think everybody has suggested proven good therapeutic options in this case. Clinical trial is always an option, if you have one open at your site for such a patient. Having said this, we don't actually know what is the best 2nd line treatment after failing adjuvant anti-PD-1 or first line anti-PD-1. There are no prospective randomized trials looking at BRAF/MEK, IPI or IPI/NIVO in this situation. From some retrospective series, IPI/NIVO seems superior to IPI alone. BRAF/MEK obviously also an option, but only for those with a BRAF mutation.

  • Apr 16, 2024

    Pending Moderator approval.
    Delete

Further Reading

Recently Updated